Clinical trial
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT00005044 · Radiation Therapy Oncology Group, Other · Completed
Key facts
| NCT number | NCT00005044 |
|---|---|
| Title | Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer |
| Official title | A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer |
| Lead sponsor | Radiation Therapy Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Casodex, Eulexin, LHRH agonist, radiation therapy |
| Enrollment | 1,579 |
| Start date | Feb 1, 2000 |
| Primary completion | Sep 1, 2012 |
| Completion | May 20, 2022 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 15, 2022 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: